The global appendage management market is poised for robust growth, with a projected valuation of US$ 352.5 Mn by 2028, up from US$ 223.9 Mn in 2021, reflecting a compound annual growth rate (CAGR) of 6.6% throughout the forecast period.
A senior healthcare analyst at FMI attributes this growth to the rising incidence of atrial fibrillation, which is becoming more common as people live longer. The condition’s high mortality and morbidity rates, particularly in relation to embolic events such as strokes, further contribute to the expanding appendage management landscape.
Mechanical appendage closure devices, in particular, are expected to present significant opportunities in the coming years. FMI’s analysis highlights the potential benefits of these devices, including their ability to effectively seal off the left atrial appendage and prevent blood clots from forming, thereby reducing the risk of stroke. As a result, mechanical appendage closure devices are poised to play a crucial role in the overall appendage management market.
To remain ahead of your competitors, request for a sample
https://www.futuremarketinsights.com/reports/sample/rep-gb-7752
Overall, FMI’s research provides a comprehensive assessment of the global demand for appendage management and sheds light on the factors driving its growth. With a focus on key market influencers and a 10-year forecast, the report offers valuable insights into this rapidly evolving industry.
Key Insights on Competitive Landscape Analysis of Global Appendage Management Market
As per the FMI analysis, given the high revenue contribution by the top five players—including Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Cardia, Inc., and Medtronic plc—holding an accumulative revenue share of nearly 89 percent, the global appendage management market showcases a highly consolidated landscape. FMI’s research also indicates that smaller players contribute approximately 11.5 percent of revenue share to the global appendage management market. A much more careful competitive landscape analysis of the global appendage management market reveals a 3-tier
segmentation—depending upon the growth stage of various companies.
- With reach wide enough in North America, Boston Scientific Corporation and AtriCure, Inc. are the clear market leaders—for endocardial and epicardial left atrial closure devices, respectively. With an accumulative share of approximately 57 percent in the appendage management market, Boston Scientific Corporation’s WATCHMAN and AtriCure, Inc.’s products are in direct competition. However, WATCHMAN is most widely implanted and trusted—boasting FDA approval and CE Mark
- Mid-stage growth companies including Abbott Laboratories and Cardia, Inc have pulled away from the top two players, in the last few years—holding approximately 32 percent market share. These companies, however, have an expansive range of product offerings. Holding nearly 14 percent in terms of revenue, Abbott Laboratories is upping its portfolio of upper and lower extremities along with popularization of the product with good clinical trial results.
- The emerging players, including SentreHEART, Inc., LifeTech Scientific Co., Ltd, Occlutech International AB, and Johnson & Johnson Services, Inc. are more focused on product innovation and differentiation within certain treatment niches, to build a strong market position in the consolidated appendage management landscape. In spite of a miniscule market share, FMI foresees notable potential of their research and development initiatives in the long run.
In terms of overall forward market strategies, key companies are projected to focus on innovating easily implantable, life-saving products for patients suffering from atrial fibrillation, thereby, eliminating the side-effects caused by drugs taken to treat atrial fibrillation. Innovative devices and better navigation and visualization technologies are expected to bring significant opportunities—translating into increased adoption of Left Atrial Appendage (LAA) closure devices by catheterization laboratories and hospitals.
Level Up Your Market Understanding – Buy Now!
https://www.futuremarketinsights.com/checkout/7752
Moreover, mergers and acquisitions will remain a key expansion strategy among players in appendage management market. FMI indicates that acquisitions in the global appendage management market would prove beneficial for the key leaders considering the increasing number of promising on-going or successful researches by emerging companies. Already in a dominant position, key players are increasingly focusing in strengthening the supply chain and distribution networks through strategic partnerships to maximize their market share.
Bonus: Key Market Influencers
- Notable success rate of appendage management procedures.
- Non-surgical, minimal invasion approach helping in fast recovery and reduced surgical and implantation complications.
- Drawback of oral anticoagulant drugs to push the demand for appendage management procedures.
Appendage management market by Category By Product Type
- Epicardial LAA Closure Devices
- Endocardial LAA Closure Device
By End User
- Hospitals
- Cath Labs
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube